FI935302A0 - Framstaellning och magnetiska egenskaper av mycket smao magnetit-dextran-partiklar - Google Patents
Framstaellning och magnetiska egenskaper av mycket smao magnetit-dextran-partiklarInfo
- Publication number
- FI935302A0 FI935302A0 FI935302A FI935302A FI935302A0 FI 935302 A0 FI935302 A0 FI 935302A0 FI 935302 A FI935302 A FI 935302A FI 935302 A FI935302 A FI 935302A FI 935302 A0 FI935302 A0 FI 935302A0
- Authority
- FI
- Finland
- Prior art keywords
- ocnetiska
- mycket
- partiklar
- magnetit
- egenskaper
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Power Engineering (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hard Magnetic Materials (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Iron (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/984,611 US5349957A (en) | 1992-12-02 | 1992-12-02 | Preparation and magnetic properties of very small magnetite-dextran particles |
Publications (2)
Publication Number | Publication Date |
---|---|
FI935302A0 true FI935302A0 (fi) | 1993-11-29 |
FI935302A FI935302A (fi) | 1994-06-03 |
Family
ID=25530702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI935302A FI935302A (fi) | 1992-12-02 | 1993-11-29 | Hyvin pienten magneetti-dekstraani-hiukkaisten valmistus ja magneettiset ominaisuudet |
Country Status (14)
Country | Link |
---|---|
US (1) | US5349957A (fi) |
EP (1) | EP0600529A3 (fi) |
JP (1) | JPH06218271A (fi) |
KR (1) | KR940013542A (fi) |
AU (1) | AU4747193A (fi) |
CA (1) | CA2107280A1 (fi) |
CZ (1) | CZ260193A3 (fi) |
FI (1) | FI935302A (fi) |
HU (1) | HUT69399A (fi) |
IL (1) | IL107617A0 (fi) |
MX (1) | MX9306009A (fi) |
NO (1) | NO934270L (fi) |
NZ (1) | NZ248701A (fi) |
SK (1) | SK135093A3 (fi) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0689430B1 (de) * | 1993-03-17 | 1997-08-13 | Silica Gel Ges.M.B.H | Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben |
DE69332120T2 (de) * | 1993-08-12 | 2003-02-27 | Advanced Magnetics Inc | Verwendung von mit polysacchariden überzogenen superparamagnetischen oxid-kolloiden |
DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
ATE274341T1 (de) * | 1995-02-24 | 2004-09-15 | Elan Pharma Int Ltd | Nanopartikel-dispersionen enthaltende aerosole |
GB9600427D0 (en) * | 1996-01-10 | 1996-03-13 | Nycomed Imaging As | Contrast media |
WO1997025073A2 (en) | 1996-01-10 | 1997-07-17 | Nycomed Imaging A/S | Contrast media |
US5855868A (en) * | 1996-04-01 | 1999-01-05 | Nycomed Imaging As | Method of T1 -weighted resonance imaging of RES organs |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
JP2002517085A (ja) * | 1998-05-26 | 2002-06-11 | バー−イラン ユニバーシティ | 磁性金属酸化物ナノ粒子の核生成および成長ならびにその使用 |
US6315709B1 (en) * | 1998-08-07 | 2001-11-13 | Stereotaxis, Inc. | Magnetic vascular defect treatment system |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
IL142896A0 (en) | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US20070160675A1 (en) * | 1998-11-02 | 2007-07-12 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising a cephalosporin |
DE19921088C2 (de) * | 1999-04-30 | 2003-08-07 | Magforce Applic Gmbh | Stent zur Offenhaltung gangartiger Strukturen |
US7169618B2 (en) * | 2000-06-28 | 2007-01-30 | Skold Technology | Magnetic particles and methods of producing coated magnetic particles |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US6976647B2 (en) * | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
ATE291899T1 (de) * | 2001-06-22 | 2005-04-15 | Marie Lindner | Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics |
PT1429731E (pt) * | 2001-09-19 | 2007-04-30 | Elan Pharma Int Ltd | Formulações de insulina nanoparticulada |
PT1443912E (pt) | 2001-10-12 | 2007-11-28 | Elan Pharma Int Ltd | Composições tendo uma combinação de características de libertação imediata e de libertação controlada |
EP1450863A4 (en) * | 2001-11-07 | 2009-01-07 | Imcor Pharmaceutical Company | PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
JP4598399B2 (ja) | 2002-02-04 | 2010-12-15 | エラン ファーマ インターナショナル,リミティド | 表面安定剤としてリゾチームを有するナノ粒子組成物 |
AU2003222027A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
KR100626096B1 (ko) * | 2002-03-26 | 2006-09-21 | 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 | 생체모방 루트에 의한 나노사이즈 산화철의 제조 방법 |
US20030185757A1 (en) * | 2002-03-27 | 2003-10-02 | Mayk Kresse | Iron-containing nanoparticles with double coating and their use in diagnosis and therapy |
WO2003082213A2 (en) * | 2002-03-28 | 2003-10-09 | Imcor Pharmaceutical Company | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |
US7462366B2 (en) * | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US6800271B2 (en) * | 2002-04-01 | 2004-10-05 | Council Of Scientific And Industrial Research | Process for the preparation of nanosized iron oxide by biomimetic route |
US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
EP2263650A3 (en) | 2002-04-12 | 2013-12-25 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US9101540B2 (en) * | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
US20040018242A1 (en) * | 2002-05-06 | 2004-01-29 | Elan Pharma International Ltd. | Nanoparticulate nystatin formulations |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
CA2488498A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
AU2003261167A1 (en) * | 2002-07-16 | 2004-02-02 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
US7842377B2 (en) | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
ES2355723T3 (es) * | 2002-09-11 | 2011-03-30 | Elan Pharma International Limited | Composiciones de agente activo en nanopartículas estabilizadas en gel. |
CA2500908A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
AU2003297260A1 (en) * | 2002-11-12 | 2004-06-03 | Elan Pharma International Ltd. | Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
WO2004058216A2 (en) * | 2002-12-17 | 2004-07-15 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
EP1587499A1 (en) * | 2003-01-31 | 2005-10-26 | Elan Pharma International Limited | Nanoparticulate topiramate formulations |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
WO2004105809A1 (en) * | 2003-05-22 | 2004-12-09 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7344491B1 (en) | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
WO2005016310A1 (en) * | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
CA2544627A1 (en) * | 2003-11-05 | 2005-05-19 | Elan Pharma International Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
FR2861994A1 (fr) * | 2003-11-12 | 2005-05-13 | Guerbet Sa | Nouvel agent de diagnostic pour l'irm dans les pathologies impliquant des proteinases |
US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
ES2526092T3 (es) * | 2004-11-16 | 2015-01-05 | Alkermes Pharma Ireland Limited | Formulaciones de olanzapina en nanopartículas inyectables |
US20090155331A1 (en) * | 2005-11-16 | 2009-06-18 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
CA2590675A1 (en) * | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
JP2008526855A (ja) * | 2005-01-06 | 2008-07-24 | エラン ファーマ インターナショナル リミテッド | ナノ粒子のカンデサルタン製剤 |
KR100637275B1 (ko) | 2005-01-28 | 2006-10-23 | 한국지질자원연구원 | 초음파를 이용하여 제조된 mri 조영제에 사용되는산화철 나노분말 및 그 제조방법과 이를 이용한 mri조영제의 제조방법과 그 mri 조영제 |
AU2006214443C1 (en) * | 2005-02-15 | 2011-11-24 | Alkermes Pharma Ireland Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
EP1863450A1 (en) * | 2005-03-16 | 2007-12-12 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
EP1865928A1 (en) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
AU2006226887A1 (en) * | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations |
AU2006235487B2 (en) * | 2005-04-12 | 2011-12-22 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
US20060246141A1 (en) * | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
JP2008535921A (ja) * | 2005-04-12 | 2008-09-04 | エラン・ファルマ・インターナショナル・リミテッド | シクロスポリンを含むナノ粒子および放出調節された組成物 |
US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
WO2006132752A1 (en) * | 2005-05-10 | 2006-12-14 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising vitamin k2 |
CN101212954A (zh) * | 2005-05-10 | 2008-07-02 | 伊兰制药国际有限公司 | 纳米粒氯吡格雷制剂 |
EA201100022A1 (ru) * | 2005-06-03 | 2011-06-30 | Элан Фарма Интернэшнл Лтд. | Способ получения композиции наночастиц мезилата иматиниба |
US20070042049A1 (en) * | 2005-06-03 | 2007-02-22 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
CA2610480A1 (en) * | 2005-06-03 | 2007-05-10 | Scott Jenkins | Nanoparticulate acetaminophen formulations |
JP2009517485A (ja) | 2005-06-08 | 2009-04-30 | エラン・ファルマ・インターナショナル・リミテッド | セフジトレンを含むナノ粒子状および制御放出組成物 |
ATE446742T1 (de) * | 2005-06-09 | 2009-11-15 | Elan Pharma Int Ltd | Nanopartikuläre ebastinformulierungen |
MX2007015882A (es) * | 2005-06-13 | 2008-03-04 | Elan Pharma Int Ltd | Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina. |
CA2612384A1 (en) * | 2005-06-15 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate azelnidipine formulations |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
EP1904041A2 (en) * | 2005-07-07 | 2008-04-02 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
CA2622200A1 (en) * | 2005-09-13 | 2007-03-22 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
JP2009508859A (ja) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
US8152839B2 (en) | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
NZ569666A (en) * | 2006-01-17 | 2011-02-25 | Philip Morris Prod | Cigarette components having encapsulated catalyst particles for reducing carbon monoxide and nitric oxide and methods of making and use thereof |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
MX2008015275A (es) * | 2006-05-30 | 2009-02-06 | Elan Pharma Int Ltd | Formulaciones de posaconazol en nanoparticulas. |
US20080213374A1 (en) * | 2006-07-10 | 2008-09-04 | Elan Pharma International Limited | Nanoparticulate sorafenib formulations |
US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
US20090238867A1 (en) * | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
JP2011520779A (ja) * | 2008-03-21 | 2011-07-21 | エラン・ファルマ・インターナショナル・リミテッド | イマチニブの部位特異的送達のための組成物および使用の方法 |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
US20120065221A1 (en) | 2009-02-26 | 2012-03-15 | Theraquest Biosciences, Inc. | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use |
FR2945950A1 (fr) | 2009-05-27 | 2010-12-03 | Elan Pharma Int Ltd | Compositions de nanoparticules anticancereuses et procedes pour les preparer |
CA2763456C (en) | 2009-05-27 | 2017-10-24 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
CA2984421C (en) | 2015-05-01 | 2024-04-09 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913521B2 (ja) * | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US4975282A (en) * | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
US4795698A (en) * | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US4827945A (en) * | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
US5219554A (en) * | 1986-07-03 | 1993-06-15 | Advanced Magnetics, Inc. | Hydrated biodegradable superparamagnetic metal oxides |
US5055288A (en) * | 1987-06-26 | 1991-10-08 | Advanced Magnetics, Inc. | Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides |
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
JP2726520B2 (ja) * | 1989-10-20 | 1998-03-11 | 名糖産業株式会社 | 有機磁性複合体 |
-
1992
- 1992-12-02 US US07/984,611 patent/US5349957A/en not_active Expired - Fee Related
-
1993
- 1993-09-20 NZ NZ248701A patent/NZ248701A/en unknown
- 1993-09-21 AU AU47471/93A patent/AU4747193A/en not_active Abandoned
- 1993-09-28 MX MX9306009A patent/MX9306009A/es unknown
- 1993-09-29 CA CA002107280A patent/CA2107280A1/en not_active Abandoned
- 1993-10-29 KR KR1019930022699A patent/KR940013542A/ko not_active Application Discontinuation
- 1993-11-08 JP JP5278122A patent/JPH06218271A/ja active Pending
- 1993-11-12 EP EP93203162A patent/EP0600529A3/en not_active Withdrawn
- 1993-11-15 IL IL10761793A patent/IL107617A0/xx unknown
- 1993-11-25 NO NO934270A patent/NO934270L/no unknown
- 1993-11-29 FI FI935302A patent/FI935302A/fi not_active Application Discontinuation
- 1993-12-01 SK SK1350-93A patent/SK135093A3/sk unknown
- 1993-12-01 CZ CZ932601A patent/CZ260193A3/cs unknown
- 1993-12-02 HU HU9303415A patent/HUT69399A/hu unknown
Also Published As
Publication number | Publication date |
---|---|
AU4747193A (en) | 1994-06-16 |
EP0600529A2 (en) | 1994-06-08 |
CA2107280A1 (en) | 1994-06-03 |
IL107617A0 (en) | 1994-02-27 |
NO934270D0 (no) | 1993-11-25 |
FI935302A (fi) | 1994-06-03 |
HUT69399A (en) | 1995-09-28 |
NO934270L (no) | 1994-06-03 |
MX9306009A (es) | 1995-01-31 |
SK135093A3 (en) | 1994-09-07 |
EP0600529A3 (en) | 1995-10-25 |
CZ260193A3 (en) | 1994-08-17 |
NZ248701A (en) | 1995-09-26 |
KR940013542A (ko) | 1994-07-15 |
US5349957A (en) | 1994-09-27 |
HU9303415D0 (en) | 1994-03-28 |
JPH06218271A (ja) | 1994-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI935302A0 (fi) | Framstaellning och magnetiska egenskaper av mycket smao magnetit-dextran-partiklar | |
FI934980A0 (fi) | Foerfarande och anordning foer utfoerande av fartygskrovs yttre ytarbete | |
FI932058A (fi) | Foerfarande foer samprocessering av organiska avfall och tvaettvatten av anvaend salpetersyra | |
FI933664A0 (fi) | Foerfarande foer framstaellning av myrsyra fraon kolmonoxid och vatten | |
FI922780A (fi) | Froebelaeggning och foerfarande foer belaeggande av froen | |
FI933225A0 (fi) | Foderprodukt och foerfarande foer framstaellning av denna | |
FI932906A (fi) | Foerfarande och anordning foer framstaellning av paket utav amorfa staolremsor foer framstaellning av transformaterkaerna | |
FI931288A0 (fi) | Anordning foer laesande och beskrivande av magnetkort | |
FI930275A0 (fi) | Hetblaosningsugn och foerfarande foer framstaellning av en hetblaosningsugn | |
FI931422A (fi) | Foerfarande och anordning foer reglering av elmotorer | |
FI934384A (fi) | Foerfarande foer avgasning och avkolning av rostfritt smaeltstaol | |
FI931221A0 (fi) | Foerfarande foer drivning av en dieselmotor och dieselmotor | |
FI930218A0 (fi) | Elektrod och foerfarande foer maetning av utjaemningseffekt | |
FI934546A (fi) | Foerfarande och anlaeggning foer bombering av glasskivor | |
FI932201A (fi) | Foerfarande foer framstaellning av koettbuljong och koettextrakt | |
FI933972A (fi) | Fuktdetekteringselement och foerfarande foer framstaellning av detta | |
FI934693A0 (fi) | Foerfarande foer desinfiering av en kontaktlins och konservering av dessbehandlingsloesning | |
FI933405A0 (fi) | Anvaendning av blandningar av mannich-akrylamidpolymerer och kvaternaerapolyaminer foer flockulering av enzymloesningsfloeden | |
FI924486A (fi) | Foerfarande och anordning foer gjutning av betongprodukter | |
FI535U1 (fi) | Anordning foer lagring och dispensering av vaetska | |
FI930697A (fi) | Foerfarande och komposition foer behandling av virusinjektion | |
FI933109A0 (fi) | Likoer och framstaellningsfoerfarande av densamma | |
FI935229A (fi) | Foerfarande foer framstaellning av pesticider och mellanprodukter | |
FI923801A (fi) | Foerening foer framstaellning av vaete och foerfarande foer framstaellning avfoereningen | |
FI920964A (fi) | Brygga och foerfarande foer byggande av densamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assigment of application |
Owner name: NANOSYSTEMS L.L.C. |
|
GB | Transfer or assigment of application |
Owner name: NANOSYSTEMS L.L.C. |
|
FD | Application lapsed |